Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals

NPPA releases Revised MRP for 543 brands of Anti-Cancer Medicines; List to be updated on continual basis; New Prices Effective from November 9, 2026

Posted On: 28 OCT 2026 6:44PM by PIB Delhi

The **National Pharmaceutical Pricing Authority (NPPA)**, under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has released a list of 543 brands of anti cancer medicines with their revised **Maximum Retail Price (MRP).** The revised MRPs will be effective from **November 9, 2026**. The revised price list reflects the information submitted by companies up to October 27, 2026 and it will be updated as and when manufacturers submit their revised prices of non-scheduled anti-cancer drugs.

Some brands of the anti cancer medicines with their pre-revised and revised prices:

Company Name	Drug Name	Strength & Dosage Form	Brand Name	Pack Size	Old MRP (₹)	Revis MRP
RPG LIFE SCIENCES LTD	Anastrozole	1 MG Tablet	ANARZOLE	10 tablets	695.76	73.0
Dr. Reddys Laboratories Limited	Azacitidine	100 MG Injection	Azacytin	1	6,337.00	1,495
Abbott Healthcare Pvt. Ltd.	Bevacizumab	100 mg/4 ml Injection	BEVACIZAB	4 ml vial	21,767.70	5,930
NATCO PHARMA LIMITED	Dasatinib	20 MG Tablet	Dasanat 20	60 tablets	2,812.50	1,085

RPG LIFE SCIENCES LTD	Denosumab	60 MG Injection	Debrumab 60 mg	1 ml PFS	22,031.25	5,941
RPG LIFE SCIENCES LTD	Enzalutamide	40 MG Capsule	Enuta	28 capsules	6,578.20	2,232
NEON LABORATORIES LIMITED	Erlotinib	150 MG Tablet	ERLIB	1 Plastic Bottle of 30 tablets	4,637.45	2,008
HETERO HEALTHCARE LTD	Fludarabine	50 MG Injection	FLUDANOX	vial	14,235.00	2,432
RPG LIFE SCIENCES LTD	Fulvestrant	50 MG Injection	Fulbreca	5 ml vial	26,072.16	5,491

The complete list of 543 brands of Anti-Cancer medicines with revised MRPs is available here. (LINK). The NPPA portal is updated on a continual basis.

On **October 17, 2026,** NPPA had announced **Trade Margin Rationalisation** (TMR) of **137 non-scheduled anti-cancer drugs** in public interest to address excessive trade margins, make cancer treatment more affordable and improve access to anti-cancer medicines. Manufacturers were instructed to submit their revised list to NPPA.

The **137 non-scheduled anti-cancer drugs** include **immunotherapy medicines** used in the treatment of over **20 types of cancer**, **Denosumab** used by **breast and prostate cancer patients**, **Pegfilgrastim** used to prevent neutropenia in cancer patients, and Bevacizumab, which is approved for the treatment of colon, ovarian and cervical cancers.

*****

PC/PM

(Release ID: 2329698) Visitor Counter : 1665
Read this release in: Urdu , हिन्दी , Tamil

Share

350 words | 1 min read